Navigation Links
Beating Blood Clots after Joint Replacement
Date:2/26/2009

Building awareness and understanding among patients is key

LAS VEGAS, Feb. 26 /PRNewswire-USNewswire/ -- As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication -- blood clots. According to findings released today at the 2009 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) (http://www.aaos.org/), deep vein thrombosis (DVT) (http://orthoinfo.aaos.org/topic.cfm?topic=A00219) a type of prophylaxis a patient receives pre and post-joint replacement, causes controversy.

"Patients undergoing total joint replacement are at high risk for DVT and pulmonary embolism (PE), unless they receive some form of prophylaxis (http://www.aaos.org/about/papers/advistmt/1027.asp)," stated Richard J. Friedman, MD, FRCSC, Clinical Professor of Orthopaedic Surgery at the Medical University of South Carolina, and Chairman, Department of Orthopaedic Surgery, Roper Hospital, in Charleston, SC. "The type of prophylaxis a patient may receive is often tailored on an individual basis, so there is not always a 'one-size fits all method' of prophylaxis available."

  • More than 700,000 primary total hip and knee replacements are performed each year in the United States, and that number is expected to grow to over 3.5 million in 2030.

On average, about 2-3 percent of people undergoing total joint replacement (http://orthoinfo.aaos.org/topic.cfm?topic=A00233) will end up with a symptomatic DVT or PE, according to Dr. Friedman.

Currently, there are several types of prophylaxis available, and are not limited to:

  • Oral agents, like warfarin
  • Injectable agents, like low molecular weight heparins
  • Mechanical compression, sleeves on a patient's legs to help stimulate blood flow

One problem patients have with warfarin, Dr Friedman explains, "is the fact it is hard to manage the dosage and requires monitoring and dose adjustment on a regular basis. There are also many food and drug interactions that can alter the effectiveness of the drug."

"Nothing is 100 percent preventable, but we can certainly cut the risk significantly and improve compliance with options such as new pharmalogical prophylaxis, especially in terms of oral agents," stated Dr. Friedman.

He feels that symptomatic rates may be cut down even more due to more prophylaxis being oral in nature. Some of these new oral agents -- which are being considered by the Food and Drug Administration -- make it more convenient to the patient and offer tremendous potential in preventing a DVT.

Whether or not these new agents become available, the best way to arm against this problem, Dr. Friedman suggests, "is to mobilize patients as early as possible to stimulate blood flow, be sure they understand that a prophylaxis or medication must be taken and how to use it, and finally, to recognize the warning signs of a potential DVT."

Even with a thorough pre-surgical evaluation, some patients are at higher risk for DVT than others having:

  • A previous blood clot
  • A family history of blood clots
  • A genetic predisposition to blood clots, such as protein-deficient

Preventing a DVT is a complex process and as with any surgery, the patient and orthopaedic surgeon should assess what method of treatment will work for the best interest of the individual patient.

Note: This topic will be the focus of a Media Briefing entitled: "Beating Blood Clots and Deciphering DVT Prophylaxis: What the Patient Needs to Know" on Thursday, February 26, in the Sands Expo Center, Venetian Hotel, Level One, Room 904 at 9:00 AM. Panelists include: Moderator: Richard J. Friedman, MD; Paul Lachiewicz, MD; and Fred Cushner, MD.

www.orthoinfo.org

About AAOS

http://www6.aaos.org/news/Pemr/releases/release_boiler.cfm?category=40&releasenum=735

    For more information, contact:

    Lauren L. Pearson
    O (847) 384-4031
    C (224) 374-8610
    lpearson@aaos.org

    Catherine Dolf
    O (847) 384-4034
    C (847) 894-9112
    dolf@aaos.org



'/>"/>
SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
2. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
3. US Testing Proves Glycn Go(TM) Increases NO in the Blood Stream
4. NicOx Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
5. Infant Blood May Provide Insights into Diseases Present at Birth
6. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
10. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
11. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- REPORT OBJECTIVES The report "SPF ... on a market segment, based on geography. Market ... the report. The primary objectives of this report ... through detailed segmentation, 2) market size and forecasts, ... market situation, trends, 3) detailed analysis of current ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
(Date:12/7/2016)... DIEGO , Dec. 7, 2016   Arena ... announced that it has completed enrollment in the ralinepag ... receptor agonist targeting the prostacyclin pathway for the treatment ... 60 patients at sites globally. "This marks ... is evidence of our strategic focus on our pipeline," ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... Students attending Envision’s summer 2017 ... get hands-on experience in an emergency medical simulation, When Care is Hours Away. ... real-life medical skills that are critical success in a future career and beyond. ...
(Date:12/7/2016)... CITY, UTAH (PRWEB) , ... December 07, 2016 ... ... today announced the release of Smart Device Remote Control through a new partnership ... across all platforms and strengthens its mobile solutions to help businesses maximize their ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now ... to restore a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. ... a variety of other treatments, to rejuvenate and renew the facial appearance. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... now promoting to the US market its advanced highly customizable contact technology solutions. ... ODU TURNTAC®. These advanced technologies are ideal for a wide range of applications ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are ... children are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas ... bring to the children of the world. , In exchange for generous donations, customers ...
Breaking Medicine News(10 mins):